Citation only
via Europe PMC
Metabolic sarcopenia in the era of incretin-based therapy: a narrative review of mitochondrial determinants of muscle quality and emerging therapeutic strategies.
Journal of Yeungnam medical science · 2026
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists and related incretin-based therapies have transformed obesity and type 2 diabetes mellitus care by producing clinically meaningful weight reductions, improving glycemic control, and modifying cardiometabolic risks. Their success has also exposed a new clinical question: Should weight loss be evaluated not only by magnitude but also by quality? In older adults and patients with obesity, diabetes, physical inactivity, chronic inflammation, or low nutritional reserve, lean mass loss during pharmacological weight reduction may contribute to or exacerbate vulnerability to metabolic sarcopenia, frailty, dysmobility, and fracture risk. Skeletal muscle is a major determinant of glucose disposal and whole-body metabolic flexibility, and mitochondrial dysfunction(definition) is increasingly recognized as a convergent mechanism linking insulin resistance, obesity, aging, and sarcopenia. Altered mitochondrial biogenesis, dynamics, mitophagy, oxidative phosphorylation, redox balance, calcium handling, and substrate selection may reinforce metabolic inflexibility and impaired muscle adaptation. Pyruvate oxidation via the pyruvate dehydrogenase complex and its regulatory kinases represents an illustrative pathway within this broader mitochondrial network. This review integrates GLP-1-based metabolic disease management, muscle health, and mitochondrial quality control. We propose a therapeutic framework that combines incretin pharmacotherapy with resistance exercise, protein and micronutrient support, monitoring of body composition and function, and investigational mitochondria-targeted strategies.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.12701/jyms.2026.43.61
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
CH, P., JH, J., & MJ., K. (2026). Metabolic sarcopenia in the era of incretin-based therapy: a narrative review of mitochondrial determinants of muscle quality and emerging therapeutic strategies. <em>Journal of Yeungnam medical science</em>. https://doi.org/10.12701/jyms.2026.43.61
Vancouver
CH P, JH J, MJ. K. Metabolic sarcopenia in the era of incretin-based therapy: a narrative review of mitochondrial determinants of muscle quality and emerging therapeutic strategies. Journal of Yeungnam medical science. 2026. doi:10.12701/jyms.2026.43.61.
BibTeX
@article{park2026Metabo,
title = {Metabolic sarcopenia in the era of incretin-based therapy: a narrative review of mitochondrial determinants of muscle quality and emerging therapeutic strategies.},
author = {Park CH and Jeon JH and Kim MJ.},
journal = {Journal of Yeungnam medical science},
year = {2026},
doi = {10.12701/jyms.2026.43.61},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in nutrition 2026
Open access · OA
Kampo medicine as a nutrition-relevant multi-target intervention for sarcopenia: implications for appetite, mitochondrial function, and the frailty-sarcopenia-cachexia continuum.
Nutrients 2020
Open access · CC-BY
Nutritional Supplements to Support Resistance Exercise in Countering the Sarcopenia of Aging
Frontiers in Endocrinology 2025
Open access · CC-BY
Mitochondrial bioenergetics dysfunction in T2DM: linking oxidative stress to insulin resistance
Frontiers in Endocrinology 2019
Open access · CC-BY
Sirtuins and Type 2 Diabetes: Role in Inflammation, Oxidative Stress, and Mitochondrial Function
Diabetes Metabolic Syndrome and Obesity 2019
Open access · CC-BY
Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship
Neuroscience & Biobehavioral Reviews 2026
Open access · CC-BY